Avidity Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avidity Biosciences, Inc. (RNA) announced participation in upcoming conferences to discuss RNA therapeutics. Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 and 23rd Annual Needham Virtual Healthcare Conference on April 10 will feature Avidity management. Live webcasts and event details will be available on the company's website.

SAN DIEGO, March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:

• Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 at 9:40 a.m. PT/ 12:40 p.m. ET
   
• 23^rd Annual Needham Virtual Healthcare Conference on April 10 at 11:15 a.m. PT/2:15 p.m. ET

A live webcast of each of the events, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity 
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302100276.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences participating in the Cantor Fitzgerald Virtual Muscular Dystrophy Symposium?

Avidity Biosciences will be participating in the Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 at 9:40 a.m. PT/ 12:40 p.m. ET.

Which conferences will Avidity Biosciences be attending?

Avidity Biosciences will be participating in the Cantor Fitzgerald Virtual Muscular Dystrophy Symposium on April 3 and the 23rd Annual Needham Virtual Healthcare Conference on April 10.

Where can investors find details about the upcoming conferences?

Investors can find up-to-date event details and archived replays on the 'Events and Presentations' page in the 'Investors' section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.